Severe phenytoin intoxication in a subject homozygous for CYP2C9*3

A 31‐year‐old woman who had a severe head injury was treated with oral phenytoin (100 mg 3 times a day) to prevent posttraumatic seizures. On day 10 of phenytoin treatment, 3 hours after the morning dose, the patient manifested neurologic signs compatible with phenytoin intoxication. Thus drug serum concentrations were monitored daily for 12 days. The elimination half‐life was 103 hours, namely, about 5 times longer than the mean value generally quoted (22 hours). In the absence of any acquired predisposing factor for phenytoin toxicity, genetic mutations in the cytochrome P450 (CYP) enzymes responsible for phenytoin metabolism (CYP2C9 and CYP2C19) were suspected. Genotyping revealed that the patient was homozygous for the CYP2C9*3 allele (CYP2C9*3/*3) and heterozygous for the CYP2C19*2 allele (CYP2C19*1/*2). In view of the markedly reduced metabolic activity of CYP2C*3 in comparison with the wild‐type enzyme (about one fifth) and of the minor role of CYP2C19 in phenytoin metabolism, it is likely that CYP2C9*3 mutation was largely responsible for drug overdose.

[1]  E. Yukawa,et al.  The Effects of Genetic Polymorphisms of CYP2C9 and CYP2C 19 on Phenytoin Metabolism in Japanese Adult Patients with Epilepsy: Studies in Stereoselective Hydroxylation and Population Pharmacokinetics , 1998, Epilepsia.

[2]  S. Higuchi,et al.  Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication. , 2000, Therapeutic drug monitoring.

[3]  G R Wilkinson,et al.  The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. , 1994, The Journal of biological chemistry.

[4]  M. Ingelman-Sundberg,et al.  Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. , 1999, Biochemical and biophysical research communications.

[5]  J. Miners,et al.  Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.

[6]  J. Brockmöller,et al.  Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. , 1999, British journal of clinical pharmacology.

[7]  J. Miners,et al.  Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. , 1993, The Biochemical journal.

[8]  G. Aithal,et al.  Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications , 1999, The Lancet.

[9]  M C Meyer,et al.  Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. , 1999, Pharmacogenetics.

[10]  W. Trager,et al.  Genetic association between sensitivity to warfarin and expression of CYP2C9*3. , 1997, Pharmacogenetics.

[11]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[12]  T. Inaba Phenytoin: pharmacogenetic polymorphism of 4'-hydroxylation. , 1990, Pharmacology & therapeutics.

[13]  K. Furusho,et al.  Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy , 1997, Clinical pharmacology and therapeutics.